Esperion Therapeutics

Esperion Therapeutics Lipid Lurkers campaign

Marketing

Esperion campaign sheds light on ‘Lipid Lurkers’ in artery walls

Fresh off earning FDA approval for label expansions for its LDL-C-lowering Nexletol and Nexlizet, Esperion has launched a new marketing campaign.

Andrea Park Jul 16, 2024 8:00am

deal

Esperion, Daiichi resolve dispute with $125M settlement

Jan 3, 2024 1:22pm

Asia map globe

Takeda, Eisai, GSK and more—Fierce Pharma Asia

Mar 31, 2023 8:27am

drugs coins pharma

Esperion hits Nexletol partner Daiichi with lawsuit

Mar 28, 2023 11:27am